Post-transplant lymphoproliferative disorder after liver transplantation: Incidence, long-term survival and impact of serum tacrolimus level

Table 5 Influence of different continuous variables on time to post-transplant lymphoproliferative disorder development, mortality and multi-organ involvement of post-transplant lymphoproliferative disorder patients

	Mean rank PTLD development ≤ 1 yr	Mean rank PTLD development ≥ 1 yr	U value	Z score	P value
Age	19.85	21.85	158	-0.50	0.61
Post-PTLD survival	20.19	21.15	167	-0.24	0.80
Tacrolimus level	16.57	14.61	86	-0.54	0.58
Tacrolimus dose	19.84	18.85	154	-0.27	0.78
Prednisolone dose	20.56	18.88	154	-0.44	0.65
	Alive patient	Deceased patient
Age	23.19	16.47	127.5	-1.78	0.74
Tacrolimus level	13.62	21.00	55	-2.11	0.03
Tacrolimus dose	18.96	20.43	175	-0.40	0.68
Prednisolone dose	19.65	20.57	171	-0.25	0.79
Mean time to PTLD	23.12	16.56	129	-1.74	0.08
	Multi-organ (+)	Multi-organ (-)
Age	19.50	19.50	176	0.00	1.00
Tacrolimus level	16.50	14.74	97	-0.54	0.58
Tacrolimus dose	20.27	18.14	146	-0.60	0.54
Prednisolone dose	19.81	19.27	171	-0.15	0.87
Post-PTLD survival	15.59	22.34	113	-1.85	0.06
Mean time to PTLD	13.62	23.77	82	-2.78	0.005

PTLD: Post-transplant lymphoproliferative disorder.